Costs and mortality of recurrent versus
            <i>de novo</i>
            hormone receptor-positive/HER2
            <sup>-</sup>
            metastatic breast cancer

Engel-Nitz, Nicole; Hao, Yanbin; Becker, Laura; Gerdes, Randall

doi:10.2217/cer.15.19

Cited by 7 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among North Carolina breast cancer survivors, yearly costs for private payers were >$75,000, and those for Medicaid were >$28,000 in 6 months (2014 US dollars) (Table ) . Among women with de novo metastatic breast cancer, costs were $9955 per month over a mean follow‐up of 332 days from diagnosis …”

Section: Resultsmentioning

confidence: 99%

“…38,39 Among women with de novo metastatic breast cancer, costs were $9955 per month over a mean follow-up of 332 days from diagnosis. 40 Similar to the older population, costs were lower in the continuing phase of care (Table 3). 18,19 Monthly net costs were up to 9 times higher for those with stage IV versus stage I disease.…”

Section: Direct Health Care Costs To All Payersmentioning

confidence: 90%

See 1 more Smart Citation

Costs of cancer along the care continuum: What we can expect based on recent literature

Pisu

Henrikson

Banegas

et al. 2018

Cancer

View full text Add to dashboard Cite

Background Cancer costs should be discussed by patients and providers, but information is not readily available. Results from recently published studies (in the last 5 years) on direct and indirect cancer costs may help guide these discussions. Methods The authors reviewed studies published between 2013 and 2017 that reported direct health care costs and indirect (productivity losses) costs. The annual mean total and net costs of cancer were summarized for all payers and for survivors only by age (ages 18‐64 and ≥65 years), by phase of care (initial [ie, 12 months from diagnosis], continuing, and end‐of‐life [ie, 12 months before death]), or for recently diagnosed (within 1‐2 years of diagnosis) and longer term survivors. Results For all payers combined, costs for cancers like breast, prostate, colorectal, and lung cancers were $20,000 to $100,000 in the initial phase, $1000 to $30,000 annually in the continuing phase, and ≥$60,000 in the end‐of‐life phase. Annual out‐of‐pocket costs to recently diagnosed survivors were >$1000 for medical care and time costs, approximately $2000 for productivity losses, and from $2500 to >$4000 for employment disability, depending on age. For longer term survivors, the cost of medical care was approximately $1500 for older survivors and $747 for younger survivors, time costs were $831 to $955 for older survivors and $459 to $630 for younger survivors, and productivity losses were approximately $800. Disability among long‐term survivors was similar to that among short‐term survivors. Limitations of the reviewed studies included older data and under‐representation of higher cost cancers. Conclusions Frequently updated cost information for all cancer types is needed to guide discussions of anticipated short‐term and long‐term cancer‐related costs with survivors. Cancer 2018;000:000‐000. © 2018 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Direct Health Care Costs To All Payersmentioning

confidence: 90%

Costs of cancer along the care continuum: What we can expect based on recent literature

Pisu

Henrikson

Banegas

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…However, this study only included patients treated at a large comprehensive cancer center, and median follow-up was just 19 months. Two other investigations demonstrated that recurrent metastatic BC conferred a survival disadvantage ( 12 , 13 ), but an analysis of human epidermal growth factor receptor 2–positive BC patients treated with trastuzumab found no survival difference for those with recurrent vs de novo disease ( 14 ). Among patients with metastatic LC, recurrence conferred a six-month survival advantage among those with a KRAS but not an EGFR mutation ( 15 ).…”

mentioning

confidence: 99%

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer

Hassett

Uno

Cronin

et al. 2018

JNCI Cancer Spectrum

View full text Add to dashboard Cite

The treatments provided to and survival of patients with recurrent vs de novo stage IV advanced breast, lung, and colorectal cancer may differ but have not been well studied. Using population-based data from the Cancer Research Network for 4510 patients with advanced breast, lung, or colorectal cancer, we matched recurrent/de novo patients on demographic factors. We found longer survival for recurrent vs de novo lung cancer (182 matched pairs); no significant difference for colorectal cancer (332 matched pairs); and shorter survival for recurrent vs de novo breast cancer (219 matched pairs). Compared with recurrent cases, chemotherapy use and radiation therapy use were more common among de novo cases. Differences in treatment and survival between recurrent and de novo advanced cancer patients could inform prognostic estimates and clinical trial design.

show abstract

“…; Engel‐Nitz et al. ), and others have generated cost estimates for metastatic disease in patients 65 years and older (Yabroff et al. ; Bradley et al.…”

mentioning

confidence: 99%

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis

Ritzwoller

Fishman

Banegas

et al. 2018

Health Services Research

View full text Add to dashboard Cite

show abstract

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2 ^- metastatic breast cancer

Abstract: Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.

Cited by 7 publications

References 36 publications

Costs of cancer along the care continuum: What we can expect based on recent literature

Costs of cancer along the care continuum: What we can expect based on recent literature

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis

Contact Info

Product

Resources

About

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2 - metastatic breast cancer

Abstract: Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.

Cited by 7 publications

References 36 publications

Costs of cancer along the care continuum: What we can expect based on recent literature

Costs of cancer along the care continuum: What we can expect based on recent literature

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis

Contact Info

Product

Resources

About

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2 ^- metastatic breast cancer